Research

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

SARS-CoV-2 within-host diversity and transmission

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Structural impact on SARS-CoV-2 spike protein by D614G substitution

Prevalence of mental disorders, suicidal ideation and suicides in the general population before and during the COVID-19 pandemic in Norway: A population-based repeated cross-sectional analysis

Spread of a variant SARS-CoV-2 in long-term care facilities in England

Tocilizumab in hospitalized patients with severe COVID-19 pneumonia

Interleukin-6 Receptor antagonists in critically ill patients with COVID-19

Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine

BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting

Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant

Paper of the month: Association Between Dispatch of Mobile Stroke Units and Functional Outcomes Among Patients With Acute Ischemic Stroke in Berlin

The fifth episode of the podcast series “One Voice for Neurology” focuses on research in neuroscience. Three guests have been interviewed: Prof. Monica di Luca, president of the European Brain Council, Jane Ransom, executive director of the American Brain Foundation and Dr. Paulo Fontoura, Global Head of Clinical Development Neuroscience at Roche.

For April 2021, we have selected: Pun B.T. et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study. Lancet Respir Med. 2021; 9:239-250. doi: 10.1016/S2213-2600(20)30552-X.